Treatment of refractory obstetric antiphospholipid syndrome: The state of the art and new trends in the therapeutic management

Lupus

Volumn 22, Issue 1, 2013, Pages 6-17

  Alijotas Reig, J ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Antiphospholipid antibody; complement activation; obstetric antiphospholipid syndrome; obstetric morbidity; refractory; treatment

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ADALIMUMAB; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; ANTIVITAMIN K; BEMIPARIN; CORTICOSTEROID; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; ETANERCEPT; FONDAPARINUX; GLUCOCORTICOID; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; PENTOXIFYLLINE; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 10; TINZAPARIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UBIDECARENONE; UNINDEXED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; COCHRANE LIBRARY; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFORMATION PROCESSING; LOW DRUG DOSE; MATERNAL HYPERTENSION; MEDLINE; META ANALYSIS; NATURAL KILLER CELL; OBSTETRIC ANTIPHOSPHOLIPID SYNDROME; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION; TREND STUDY;

ANTIPHOSPHOLIPID SYNDROME; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84871539112     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312465782     Document Type: Review

References (135)

1. Yamaguchi Y, Noriyuki N, Kaburaki J, et al. Excessive exposure to anionic surfaces maintains autoantibody response to B2-glycoprotein I in patients with antiphospholipid syndrome. Blood. 2007 ; 110: 4312-4318
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006 ; 4: 295-306
3. Alijotas-Reig J. Towards the comprehension of the heterogeneity of clinical manifestations related with antiphospholipid antibodies. Med Clin [Barc]. 2005 ; 125: 187-189
4. Boffa M-C, Boinot C, de Carolis S, et al. Laboratory criteria of the obstetrical antiphospholipid syndrome [APS]. Data from a multicentre prospective European women cohort. Thromb Haemost. 2009 ; 102: 25-28
5. Meroni P, Raschi E, Grossi C, et al. Obstetric and vascular APS: Same autoantibodies but different diseases?. Lupus. 2012 ; 21: 708-710
6. Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnancy-a systematic review of randomized therapeutic trials. Thromb Res. 2004 ; 114: 419-426
7. Danza A, Ruiz-Irastorza G, Khamashta MA. Antiphospholipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynecol. 2012 ; 26: 65-76
8. Scoble T, Wijetilleka S, Khamashta MA. Management of refractory anti-phospholipid syndrome. Autoimmunity Rev. 2011 ; 10: 669-673
9. Bates SM. Consultative hematology: the pregnant patient pregnancy loss. Haematology Am Soc Hematol Educ Program. 2010 ; 2010: 166-172
10. Simchen MJ, Dulitzki M, Rofe G, et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand. 2011 ; 90: 1428-1433
11. Di Prima FAF, Valenti O, Hyseni E, et al. Antiphospholipid syndrome during pregnancy: the state of the art. J Perinatal Med. 2011 ; 5: 41-53
12. Alijotas-Reig J, Ferrer-Oliveras R. The European Registry on Obstetric Antiphospholipid Syndrome [EUROAPS]: A preliminary first year report. Lupus. 2012 ; 21: 766-768
13. de Jesus GR, dos Santos FC, Oliveira CS, et al. Management of obstetric antiphospholipid syndrome. Curr Rheumatol Rep. 2012 ; 14: 79-86
14. Cohen D, Berger SP, Steup-Beekman MA, et al. Diagnosis and management of antiphospholipid syndrome. BMJ. 2010 ; 340: 1125-1132
15. Ruiz-Irastorza G, Egurbide MV, Ugalde J, et al. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004 ; 164: 77-78
16. Ruiz-Iratorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010 ; 376: 1498-1509
17. Drakeley AJ, Quenby S, Farquharson R. Mid-trimester loss-appraisal of a screening protocol. Hum Reprod. 1998 ; 13: 1975-1980
18. Galarza-Maldonado C, Kourilovitch MA, Perez-Fernandez OM, et al. Obstetric antiphospholipid syndrome. Autoimmun Rev. 2012 ; 11: 288-295
19. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and pattern of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 ; 46: 1019-1027
20. Ferrer-Oliveras R, Llurba E, Cabero-Roura L, et al. Prevalence and clinical usefulness of antiphospholipid and anti-cofactor antibodies in different Spanish preeclampsia subsets. Lupus. 2012 ; 21: 257-263
21. Gomez-Puerta JA, Sanin-Blair J, Galarza-Maldonado C. Pregnancy and catastrophic antiphospholipid syndrome. Clin Rev Allergy Immunol. 2009 ; 36: 85-90
22. Meroni PL. Endothelial cell perturbation by anti-phospholipid antibodies in systemic lupus erythematosus. Lupus. 2007 ; 16 (suppl). 17-19
23. Koike T. Antiphospholipid antibodies and cell activation. Lupus. 2007 ; 16 (suppl). 17-17
24. Meroni PL, Borghi MO, Raschi E, Ventura D, et al. Inflammatory response and the endothelium. Thromb Res. 2004 ; 114: 329-334
25. Asherson RA, Cervera R, Wells AU. Diffuse alveolar haemorrhage: a non-thrombotic antiphospholipid lung syndrome?. Semin Arthritis Rheum. 2005 ; 35: 138-142
26. Asherson RA, Cervera R, Shepshelovich D, et al. Non-thrombotic manifestations of the antiphospholipid syndrome: away from thrombosis?. J Rheumatol. 2006 ; 33: 1038-1044
27. Alijotas-Reig J, Vilardell-Tarrés M. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?. Obstet Gynecol Surv. 2010 ; 65: 39-45
28. Out HJ, Kooijman CD, Bruinse HW, et al. Histopathological findings in placenta from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynaecol Reprod Biol. 1991 ; 195: 211-220
29. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid- induced fetal loss by inhibiting complement activation. Nature Med. 2004 ; 10: 1222-1226
30. Girardi G, Berman J, Redecha P. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003 ; 112: 1644-1654
31. Holers VM, Girardi G, Mo L. Complement C3 activation is required for antiphospholipid antibody induced fetal loss. J Exp Med. 2002 ; 195: 211-220
32. Meroni PL, di Simone N, Testoni C, et al. Antiphospholipid antibodies as cause of pregnancy loss. Lupus. 2004 ; 13: 649-652
33. Magid MS, Kaplan C, Sammaritano LR, et al. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol. 1998 ; 179: 226-234
34. Holmes CH, Simpson KL. Complement and pregnancy: new insights into the immunobiology of the fetal-maternal relationship. Balliere's Clin Obstet Gynecol. 1992 ; 6: 439-459
35. Cunningham DS, Tichenor JR. Decay-accelerating factor protects human trophoblast from complement-mediated attack. Clin Immunol Immunopathol. 1995 ; 74: 156-161
36. Alijotas-Reig J. The immunological puzzle of recurrent miscarriage. Curr Immunol Rev. 2009 ; 5: 175-186
37. Quenby S, Bates M, Doig T, et al. Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Hum Reprod. 1999 ; 14: 2386-2391
38. Tuckerman E, Laird S, Prakash A, et al. Prognostic value of the measurement of uterine natural killer cells in the endometrium of women with recurrent miscarriage. Hum Reprod. 2007 ; 22: 2208-2213
39. Szekeres-Bartho J, Faust Z, Varga P, et al. The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production. Am J Reprod Immunol. 1996 ; 35: 348-351
40. Carp HJA, Shoenfeld Y. Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells-an additional mechanism in a multifactorial process. Rheumatology. 2007 ; 46: 1517-1519
41. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999 ; 42: 71-75
42. Szekeres-Bartho J, Kilar F, Falkay G, et al. The mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity: I. Progesterone-treated lymphocytes of healthy pregnant women release a factor inhibiting cytotoxicity and prostaglandin synthesis. Am J Reprod Immunol Microbiol. 1985 ; 9: 15-19
43. Faust Z, Laskarin G, Rukavina D, et al. Progesterone induced blocking factor inhibits degranulation of NK cells. Am J Reprod Immunol. 1999 ; 42: 71-75
44. Carp HJA, Shoenfeld Y. Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells-an additional mechanism in a multifactorial process. Rheumatology. 2007 ; 46: 1517-1519
45. Perricone C, De Carolis C, Giaccomelli R, et al. High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. Rheumatology. 2007 ; 46: 1574-1578
46. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2005 ; 174: 1222-1226
47. Meroni PL, Borghi MO, Raschi E, et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011 ; 7: 330-339
48. Di Simone N, Meroni PL, D'Asta M, et al. Pathogenic role of anti-β2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update. 2007 ; 13: 189-196
49. Di Simone N, Di Nicuolo F, D'Ippolito S, et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod. 2010 ; 83: 212-219
50. D'Ippolito S, Marana R, Di Nicuolo F, et al. Effect of low molecular weight heparins on antiphospholipid antibodies-mediated inhibition of endometrial angiogenesis. PLoS ONE. 2012 ; 7: e29660 - e29660
51. Derksen RH, de Groot PG. Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus. 2010 ; 19: 470-474
52. Ruiz-Irastorza G, Cuadrado M, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report to a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus. 2011 ; 20: 206-218
53. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilias, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [8th edn]. Chest. 2008 ; 133 (6 Suppl): 844S - 886S
54. Bates SM. Consultative hematology: the pregnant patient pregnancy loss. Haematology Am Soc Hematol Educ Program. 2010 ; 2010: 166-172
55. Espinosa RG, Pierangeli SS, Gharavi AE, et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholid antibodies. Thromb Haemost. 2002 ; 87: 518-522
56. Edwards MH, Pierangeli SS, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997 ; 96: 4380-4384
57. Hills FA, Abrahams VM, Gonzalez-Timón B, et al. Heparin prevents programmed cell death in human trophosblast. Mol Hum Reprod. 2006 ; 12: 237-243
58. Oberkersch R, Attoresi A, Calabrese GC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res. 2010 ; 125: e240-245
59. Lim W. Complement and the antiphospholipid syndrome. Curr Opinion Hematol. 2011 ; 18: 361-365
60. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid- induced fetal loss by inhibiting complement activation. Nat Med. 2004 ; 10: 1226-1226
61. Carr JA, Cho JS. Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis. Ann Vasc Surg. 2007 ; 21: 50-55
62. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004 ; 10: 1222-1226
63. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide [fondaparinux]. Thromb Res. 2003 ; 109: 1-11
64. Banzato A, Frasson R, Acqusaliente L, et al. Circulating B2glycoprotein I-IgG anti-B2glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome. Lupus. 2012 ; 21: 784-786
65. Amara U, Fliert MA, Rittirsch D, et al. Molecular intercommunications between the complement and coagulation systems. J Immunol. 2010 ; 185: 5268-5236
66. Da Pozzo E, Barsoti MC, Benditelli S, et al. Differential effects of fondaparinux and bemiparin on angiogenic and vasculogenesis-like processes. Thromb Res 2012; 130: e113-122.
67. Ben-Hadj-Khalifa S, Hézard N, Almawi WY, et al. IL-10 modulates fondaparinux inhibition of monocyte-induced thrombin generation. J Throm Thrombolysis. 2011 ; 32: 311-317
68. Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Invest. 2011 ; 41: 672-678
69. Wozniacka A, Lesiak A, Narbutt JM, et al. Chloroquine treatment influences proinflammatory cytokine level in systemic lupus erythematosus patients. Lupus. 2006 ; 15: 268-275
70. Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood. 2004 ; 104: 2783-2790
71. Hunt BJ, Wu XX, de Laat B, et al. Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol. 2011 ; 205: 485.e17-23.6
72. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010 ; 115: 2292-229
73. Rand JH, Wu XX, Quinn As , et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol. 2003 ; 163: 1193-1200
74. Rand J, Wu X, Quinn A, et al. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010 ; 19: 460-469
75. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin [ESPRIT]: randomised controlled trial. Lancet. 2006 ; 367: 1665-1673
76. Levine SR, Brey RL, Joseph CL, et al. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group. Stroke. 1992 ; 23 (2 Suppl). 129-132
77. George EM, Cockrell K, Adair TH, et al. Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic condition in rat placental villous explants. Am J Physiol Regul Integr Comp Physiol. 2010 ; 299: R1629-1633
78. Duley L, Henderson-Smart DJ, Meher S, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane database Syst Rev. 2007 ; 18: CD004659 - CD004659
79. Vivaldi P, Andreotti C, Mazzoni C, et al. A primitive catastrophic antiphospholipid syndrome. Haematologica. 1994 ; 79: 173-176
80. Burcoglu-O'Ral A, Erkan D, Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol. 2002 ; 29: 2006-2011
81. Lubbe W, Butler W, Palmer S, et al. Fetal survival after prednisone suppression of maternal lupus anticoagulant. Lancet. 1983 ; 1: 1361-1363
82. Axelrod L. Glucocortiocoids. In: Kelley NK, Harris ED, Ruddy S, Sledge C (eds) Textbook of rheumatology. 4th ed. Philadelphia, W.B. Saunders Co, 1993, vol 1, pp.779-796.
83. Sneiderman C, Wilson J. Effects of corticosteroids on complement and the neutrophil polymorphonuclear leukocyte. Transplant Proc. 1975 ; 1: 1361-1363
84. Quenby S, Farquharson R, Young M, et al. Successful pregnancy outcome following 19 consecutive miscarriages. Hum Reprod. 2003 ; 18: 2562-2564
85. Bramham K, Thomas M, Nelson-Piercy C, et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood. 2011 ; 117: 6948-6951
86. Laskin CA, Bombardieri C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997 ; 337: 148-153
87. Benediktsson R, Calder A, Edwards C, et al. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol [Oxf]. 1997 ; 46: 161-166
88. Akther A, Faridi RM, Das V, et al. In vitro up-regulation of HLA-G using dexamethasone and hydrocortisone in first-trimester trophoblast cells of women experiencing recurrent miscarriage. Tissue Antigens 2012; 80: 126-135.
89. Bayry J, Negi VS. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011 ; 7: 349-359
90. Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. 2006 ; 2: CD000112 - CD000112
91. Perricone R, De Carolis C, Kröegler B, et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology. 2008 ; 47: 646-651
92. Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2010 ; 12: 70-76
93. Tuthill J, Khamashta M. Management of antiphospholipid syndrome. J Autoimmun. 2009 ; 33: 92-98
94. Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulins in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum. 2003 ; 48: 728-731
95. Branch D, Peaceman A, Druzin M, et al. A multicenter placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. 2000 ; 182: 122-127
96. Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet. 2009 ; 104: 223-225
97. Lopera-Vallejo AF, Alijotas-Reig J. Antiphospholipid antibodies and recurrent implantation failure in in-vitro fertilization. The debate goes on. Med Clin [Barc]. 2011 ; 137: 697-701
98. Szodoray P, Bacskó G, Lakos G, et al. Combined therapy in pregnancy with primary antiphospholipid syndrome. Orv Hetil. 2003 ; 144: 2411-2413
99. Vaquero E, Lazzarin N, Valensise H, et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisolone plus low-dose aspirin. Am J Reprod Immunol. 2001 ; 45: 174-179
100. Carp HJA. Intravenous immunoglobulin: effect on infertility and recurrent pregnancy loss. Israel Medical Association Journal (IMAJ). 2007 ; 9: 877-880
101. Moraru M, Carbone J, Alecsandru D, et al. Intravenous immunoglobulin treatment increased live birth rate in a Spanish of women with recurrent reproductive failure and expanded CD56[+] cells. Am J Reprod Immunol 2012; 68: 75-84.
102. Ensom MH, Stephenson MD. A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. Hum Reprod. 2011 ; 26: 2283-228
103. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs. 2005 ; 65: 661-694
104. Ramos-Casals M, Brito-Zeron P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies. Medicine (Baltimore). 2007 ; 86: 242-251
105. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Journal of American Medical Association (JAMA). 2006 ; 295: 2275-2285
106. Berthelot JM, De Bandt M, Goupille P, et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine. 2009 ; 76: 28-34
107. Salmon JE, Alpert D. Are we coming to terms with tumor necrosis factor inhibition in pregnancy?. Arthritis Rheum. 2006 ; 54: 2353-235
108. Rosner I, Haddad A, Boulman N, et al. Pregnancy in rheumatology patients exposed to anti-tumor [TNF]-alpha therapy. Rheumatology. 2007 ; 46: 1508-1509
109. Bank LHB. Unexpected dramatic clinical response of psoriasis lesions and unexpected pregnancy in an infertile patient in response to treatment with anti-tumor necrosis factor monoclonal antibody for Crohn's disease. Am J Gastroenterol. 2002 ; 97 (Abstract). S260 - S260
110. Ramos-Casals M, Roberto-Perez-Alvarez , Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev. 2010 ; 9: 188-193
111. Winger EE, Reed JL, Ashoush S, et al. Treatment with Adalimumab [HumiraR] and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol. 2009 ; 61: 113-120
112. Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol. 2008 ; 60: 8-16
113. Beer AE. Th-1/Th-2 natural killer cell activation systemically and locally in the endometrium and therapeutic options. Am J Reprod Immunol. 2001 ; 45: 23-23
114. Mangubat CP, Thaker PP, Cavalcante M, et al. Etanercept and immune treatment in multiple IVF failures. Am J Reprod Immunol. 2001 ; 45: 24-24
115. Chaouat G, Assal-Meliani A, Martal J, et al. IL-10 prevents naturally occurring fetal loss in the CBAxDBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau. J Immunol. 1995 ; 154: 426-428
116. Zhong XH, Shi WY, Ma AT, et al. Effects of Radix scutellariae and Rhizoma atractylodis on LPS-induced abortion and the uterine IL-10 contents in mice. Am J Chin Med. 2008 ; 36: 141-148
117. Shaw SM, Shah MKH, Williams SG, et al. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Cardiol. 2009 ; XX: 113-118
118. Lu D, Song H, Li Y, et al. Pentoxifylline for endometriosis. Cochrane Database Syst Rev. 2012 ; 1: CD007677 - CD007677
119. Creus M, Fabregues F, Carmona F, et al. Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial. Hum Reprod. 2008 ; 23: 1910-1916
120. Bick RL. Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost. 2001 ; 7: 241-258
121. Letur-Konirsch H, Delanian S. Successful pregnancies after combined pentoxifylline-tocopherol treatment in women with premature ovarian failure who are resistant to hormone replacement therapy. Fertil Steril. 2003 ; 79: 439-441
122. Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood 2012; 119: 5859-5870.
123. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis. 2007 ; 66: 1137-1142
124. Agmon-Levin N, Blank M, Zandman-Goddard G, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011 ; 70: 145-150
125. Hughes G. Hughes syndrome: the antiphospholipid syndrome -a clinical overview. Clin Rev Allergy Immunol. 2007 ; 32: 3-12
126. Pierangeli SS, Vega-Ostertag ME, Gonzalez EB. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med. 2007 ; 9: 1-15
127. Raschi E, Borghi MO, Grossi C, et al. Toll-like receptors: another player in the pathogenesis of the antiphospholipid syndrome. Lupus. 2008 ; 87: 214-220
128. Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006 ; 36: 361-370
129. Broussas M, Cornillet- Levefre P, Potron G, et al. Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of the A3 adenosine receptor. Thromb Haemost. 2002 ; 88: 123-130
130. Burcuglu-O'Ral A, Erkan D, Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide: a proposed vascular endothelial cell modulator. J Rheumatol. 2002 ; 29: 2006-2011
131. Napoleone E, Di Santo A, Camera M, et al. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res. 2002 ; 86: 139-143
132. J, Mahmud SA, Bitterman PB, et al. Histone deacetylase inhibitors suppress TF-KappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Biol Chem. 2007 ; 282: 24-408-24418
133. Kinev AV, Roubey RAS. Tissue factor in the antiphospholipid syndrome. Lupus. 2008 ; 17: 952-958
134. Raschi E, Borghi MO, Grossi C, et al. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus. 2008 ; 17: 937-942
135. Lockhin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012 ; 64: 2311-2318